Search

Your search keyword '"MESH: Melphalan"' showing total 6 results
Start Over Descriptor "MESH: Melphalan" Publisher hal ccsd
6 results on '"MESH: Melphalan"'

1. [Current treatment of AL amyloidosis]

Author

Desport, Estelle, Moumas, Eric, Abraham, Julie, Delbès, Sébastien, Lacotte-Thierry, Laurence, Touchard, Guy, Fermand, Jean-Paul, Bridoux, Franck, Jaccard, Arnaud, Service de néphrologie - hémodialyse et transplantation rénale, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Centre National de la Recherche Scientifique (CNRS)-Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], and Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS)

Subjects
MESH: Immunoglobulin Light Chains, Consensus Development Conferences as Topic, Paraproteinemias, Kaplan-Meier Estimate, Dexamethasone, MESH: Kidney Transplantation, Bortezomib, MESH: Paraproteinemias, Natriuretic Peptide, Brain, MESH: Renal Dialysis, MESH: Natriuretic Peptide, Brain, MESH: Peptide Fragments, Lenalidomide, Melphalan, Randomized Controlled Trials as Topic, MESH: Thalidomide, MESH: Heart Transplantation, Amyloidosis, Prognosis, Boronic Acids, Thalidomide, MESH: Kidney Failure, Chronic, Pyrazines, MESH: Paraproteins, MESH: Pyrazines, MESH: Dexamethasone, [SDV.IMM]Life Sciences [q-bio]/Immunology, Drug Therapy, Combination, MESH: Boronic Acids, Cardiomyopathies, Amyloid, MESH: Prognosis, MESH: Melphalan, Renal Dialysis, Humans, MESH: Amyloidosis, MESH: Kaplan-Meier Estimate, MESH: Amyloid, MESH: Humans, MESH: Consensus Development Conferences as Topic, MESH: Biological Markers, Kidney Transplantation, Peptide Fragments, MESH: Drug Therapy, Combination, MESH: Randomized Controlled Trials as Topic, MESH: Cardiomyopathies, Heart Transplantation, Kidney Failure, Chronic, Immunoglobulin Light Chains, Biomarkers, Paraproteins
Abstract

International audience; Systemic AL amyloidosis is a rare complication of monoclonal gammopathies. Renal manifestations are frequent, mostly characterized by heavy proteinuria, with nephrotic syndrome and renal failure in more than half of the patients at diagnosis. Without treatment, median survival does not exceed 12 months. Amyloid heart disease and diffusion of amyloid deposits are associated with reduced survival. Treatment of systemic AL amyloidosis has been profoundly modified with the introduction of international criteria for the definition of organ involvement and hematologic response, and with the use of sensitive tests for the measurement of serum-free light chain levels. Melphalan plus dexamethasone is now established as the gold standard for first line treatment of systemic AL, with similar efficacy and reduced treatment-related mortality compared to high-dose therapy. Modern chemotherapy regimens, based on the use of novel agents such as bortezomib and lenalidomide, might further improve patient survival.

Published
2011
Full Text
View/download PDF

2. [Kappa light chain deposition disease, presenting as Sjögren's syndrome, successfully treated by high-dose melphalan and autologous blood stem transplantation]

Author

C, Foguem, B, Kantelip, E, Deconinck, C, Hafsaoui, N, Méaux-Ruault, H, Gil, N, Magy-Bertrand, J-L, Dupond, Saas, Philippe, Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service d'Anatomie pathologique [CHRU Besançon], Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC)

Subjects
MESH: Sialography, MESH: Salivary Glands, Sialography, [SDV.IMM] Life Sciences [q-bio]/Immunology, Biopsy, Paraproteinemias, MESH: Immunoglobulin kappa-Chains, Transplantation, Autologous, Salivary Glands, Diagnosis, Differential, MESH: Electromyography, Immunoglobulin kappa-Chains, MESH: Biopsy, MESH: Melphalan, MESH: Paraproteinemias, MESH: Diagnosis, Differential, Humans, Melphalan, MESH: Humans, MESH: Hypertrophy, Electromyography, Peripheral Nervous System Diseases, Hypertrophy, MESH: Transplantation, Autologous, Sjogren's Syndrome, MESH: Sjogren's Syndrome, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, MESH: Peripheral Nervous System Diseases, MESH: Stem Cell Transplantation, Tomography, X-Ray Computed, MESH: Tomography, X-Ray Computed, MESH: Female, Stem Cell Transplantation
Abstract

International audience; INTRODUCTION: Light chain deposition disease is a systemic disorder characterised by tissue deposition of monoclonal immunoglobulin light chains without tinctorial properties. It has been exceptionally reported with salivary involvement mimicking Sjögren's syndrome and peripheral neuropathy. CASE REPORT: We report a case of light chain deposition disease associated with plasma cell dyscrasia presenting as sicca syndrome with salivary glands hypertrophy and polyneuropathy successfully treated by high dose melphalan and autologous blood stem transplantation. CONCLUSION: Light chain deposition disease should be recognized as an aetiology of sicca syndrome and peripheral neuropathy. Further studies should assess the prevalence of sicca syndrome in light chain deposition disease and better characterise the neurological manifestations.

Published
2009
Full Text
View/download PDF

3. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis

Author

Jean-Michel Goujon, Frank Bridoux, Frédéric Favreau, Antoine Thierry, Annick Delcourt, Daniel Herpin, Shaida Varnous, Arnaud Jaccard, Aude Mignot, Jean Marc Gombert, Guy Touchard, Myriam Pujo, Service de Néphrologie-Hémodialyse-Transplantation rénale [CHU Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de Cardiologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Biochimie [Poitiers], Service d'Hématologie biologique [CHU Limoges], and CHU Limoges

Subjects
Graft Rejection, Male, Melphalan, Nephrotic Syndrome, medicine.medical_treatment, Paraproteinemias, 030204 cardiovascular system & hematology, Gastroenterology, Dexamethasone, 0302 clinical medicine, Autologous stem-cell transplantation, MESH: Paraproteinemias, Secondary Prevention, Medicine, 030212 general & internal medicine, Heart transplantation, MESH: Middle Aged, Peripheral Nervous System Diseases, MESH: Heart Transplantation, Amyloidosis, Hematology, Middle Aged, 3. Good health, surgical procedures, operative, MESH: Dexamethasone, MESH: Immunoglobulin lambda-Chains, [SDV.IMM]Life Sciences [q-bio]/Immunology, Drug Therapy, Combination, MESH: Peripheral Nervous System Diseases, medicine.drug, medicine.medical_specialty, MESH: Immunoglobulin kappa-Chains, MESH: Graft Rejection, Immunoglobulin kappa-Chains, 03 medical and health sciences, MESH: Melphalan, Immunoglobulin lambda-Chains, Internal medicine, AL amyloidosis, Humans, MESH: Amyloidosis, Heart Failure, MESH: Humans, business.industry, Restrictive cardiomyopathy, medicine.disease, MESH: Male, Surgery, MESH: Recurrence, Transplantation, MESH: Drug Therapy, Combination, Heart failure, MESH: Heart Failure, Heart Transplantation, MESH: Nephrotic Syndrome, business
Abstract

International audience; Recurrence in the allograft and progression in other organs increase mortality after cardiac transplantation in AL amyloidosis. Survival may be improved after suppression of monoclonal light chain (LC) production following high dose melphalan and autologous stem cell transplantation (HDM/ASCT). However, because of high treatment related mortality, this tandem approach is restricted to few patients without significant extra-cardiac involvement. A diagnosis of systemic AL amyloidosis was established in a 45-year old patient with congestive heart failure related to restrictive cardiomyopathy, nephrotic syndrome, peripheral neuropathy, postural hypotension, macroglossia, and lambda LC monoclonal gammopathy. After melphalan and dexamethasone (M-Dex) therapy, which resulted in 80% reduction of serum free lambda LC, he underwent orthotopic cardiac transplantation. Two years later, he remains in a sustained hematologic remission, with no evidence of allograft or extra-cardiac amyloid accumulation. M-Dex should be considered as an alternative therapy in AL amyloid heart transplant recipients ineligible for HDM/ASCT.

Published
2008
Full Text
View/download PDF

4. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)

Author

Patrice Chevalier, Reza Tabrizi, Hervé Tilly, Bruno Lioure, Eric Deconinck, Gérard Socié, Jill-Patrice Cassuto, Lionel Ades, Didier Blaise, Mauricette Michallet, Mathieu Kuentz, Michel Attal, Pierre Bordigoni, Thierry Facon, Frédéric Garban, Jean-Paul Vernant, Stéphane Vigouroux, Noel Milpied, Marc Bernard, Norbert Ifrah, Jean-Henri Bourhis, Marc Renaud, Raphaël Porcher, Centre Hospitalier Universitaire [Rennes], Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire d'Hématologie [Purpan], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Hôpital Haut-Lévêque, Université Sciences et Technologies - Bordeaux 1-CHU Bordeaux [Bordeaux], Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon, Laboratoire d'Immunologie, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet, Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Claude Huriez [Lille], CHU Lille, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital de la Milétrie, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service d'Hématologie, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service d'onco-hématologie, CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Saas, Philippe, Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Sciences et Technologies - Bordeaux 1 (UB)-CHU Bordeaux [Bordeaux], and Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC)

Subjects
Male, Oncology, MESH: Remission Induction, Transplantation Conditioning, MESH: Busulfan, medicine.medical_treatment, Graft vs Host Disease, MESH: Antibodies, Monoclonal, 0302 clinical medicine, MESH: Antilymphocyte Serum, Antineoplastic Combined Chemotherapy Protocols, Melphalan, Etoposide, MESH: Etoposide, MESH: Transplantation Conditioning, MESH: Treatment Outcome, Hematology, MESH: Middle Aged, Remission Induction, Hematopoietic Stem Cell Transplantation, Antibodies, Monoclonal, Total body irradiation, 3. Good health, Survival Rate, MESH: Antineoplastic Combined Chemotherapy Protocols, 030220 oncology & carcinogenesis, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, Graft vs Leukemia Effect, RIC allogeneic transplantation, Disease-Free Survival, 03 medical and health sciences, MESH: Melphalan, Humans, Cyclophosphamide, Aged, Antilymphocyte Serum, Retrospective Studies, MESH: Humans, MESH: Cyclophosphamide, MESH: Adult, MESH: Retrospective Studies, Survival Analysis, Regimen, MESH: Disease-Free Survival, MESH: Female, Busulfan, MESH: Combined Modality Therapy, T-Lymphocytes, MESH: Carmustine, Kaplan-Meier Estimate, MESH: Proportional Hazards Models, MESH: Lymphoma, Non-Hodgkin, hemic and lymphatic diseases, MESH: Cytarabine, MESH: Data Collection, MESH: Kaplan-Meiers Estimate, MESH: Aged, Data Collection, Lymphoma, Non-Hodgkin, Cytarabine, Middle Aged, Combined Modality Therapy, Fludarabine, MESH: Salvage Therapy, Treatment Outcome, medicine.anatomical_structure, MESH: Survival Analysis, MESH: Vidarabine, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, France, MESH: Whole-Body Irradiation, Vidarabine, Whole-Body Irradiation, medicine.drug, Adult, MESH: Survival Rate, MESH: Graft vs Host Disease, Internal medicine, medicine, MESH: Transplantation, Homologous, Transplantation, Homologous, MESH: Hematopoietic Stem Cell Transplantation, Proportional Hazards Models, Salvage Therapy, Chemotherapy, business.industry, MESH: Graft vs Leukemia Effect, Carmustine, low-grade lymphoma, MESH: Male, Surgery, Transplantation, MESH: France, MESH: T-Lymphocytes, Bone marrow, business, 030215 immunology
Abstract

International audience; BACKGROUND AND OBJECTIVES: High-dose chemotherapy with allogeneic stem cell transplantation (SCT) has proven to be a successful treatment for low-grade lymphoma (LGL), but is associated with considerable transplant-related mortality (TRM). In an effort to reduce toxic mortality while maintaining the graft-versus-leukemia effect, allogeneic SCT has been combined with a reduced-intensity conditioning (RIC) regimen. The aim of this study was to determine the outcome of patients with LGL treated with RIC allogeneic SCT. DESIGN AND METHODS: This retrospective multicenter study included 73 patients with relapsed or refractory LGL allografted after a RIC regimen between 1998 and 2005 whose data were recorded in a French registry. RESULTS: Patients received a median of three lines of therapy prior to RIC allogeneic SCT. The most widely used conditioning regimens were fludarabine + busulfan + antithymocyte globulin (n=43) and fludarabine + total body irradiation (n=21). Prior to allografting, patients were in complete response (CR; n=21), partial response (PR; n=33) or had chemoresistant disease (n=19). The median follow-up was 37 months (range, 16 to 77 months). In patients in CR, PR and chemoresistant disease, the 3-year overall survival rates were 66%, 64% and 32%, respectively, while the 3-year event-free survival rates were 66%, 52% and 32%, respectively. The 3-year cumulative incidences of TRM were 32%, 28% and 63%, respectively. The incidence of relapse was 9.6%. INTERPRETATION AND CONCLUSIONS: Although associated with significant TRM, RIC allogeneic SCT in advanced chemosensitive disease leads to long-term survival.

Published
2007

5. [Treatment of AL amyloidosis, current data]

Author

A, Jaccard, Physiologie Moléculaire de la Réponse Immune et des Lymphoproliférations (PMRIL), and Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Amyloid, MESH: Remission Induction, Anti-Inflammatory Agents, MESH: Antineoplastic Agents, Alkylating, Dexamethasone, MESH: Melphalan, Humans, Multicenter Studies as Topic, MESH: Amyloidosis, Antineoplastic Agents, Alkylating, Melphalan, ComputingMilieux_MISCELLANEOUS, MESH: Hematopoietic Stem Cell Transplantation, Randomized Controlled Trials as Topic, MESH: Amyloid, MESH: Humans, Remission Induction, Hematopoietic Stem Cell Transplantation, Amyloidosis, MESH: Drug Therapy, Combination, MESH: Randomized Controlled Trials as Topic, MESH: Anti-Inflammatory Agents, MESH: Dexamethasone, MESH: Multicenter Studies as Topic, [SDV.IMM]Life Sciences [q-bio]/Immunology, Drug Therapy, Combination
Abstract

International audience

Published
2006
Full Text
View/download PDF

6. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects

Author

Philippe Quittet, Eric Legouffe, Jean-Pierre Daurès, Valérie Rouille, Marie-Cécile Bozonnat, Bernard Klein, Tarik Kanouni, Jean-François Rossi, Nathalie Fegueux, Carole Exbrayat, Ernesto Lopez, Zhao Yang Lu, John Widjenes, Robert Navarro, Service d'hématologie et oncologie médicale, Hôpital Lapeyronie-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Unité de Thérapie Cellulaire et Génique, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi, Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Diaclone Research, Frei, Monique, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Saint Eloi (CHRU Montpellier), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)

Subjects
Melphalan, Male, medicine.medical_treatment, Anti-Inflammatory Agents, Pilot Projects, MESH: Multiple Myeloma, Pharmacology, Dexamethasone, autologous transplantation, MESH: Antibodies, Monoclonal, chemistry.chemical_compound, 0302 clinical medicine, Autologous stem-cell transplantation, Multiple myeloma, MESH: Aged, 0303 health sciences, MESH: Middle Aged, MESH: Mucositis, Antibodies, Monoclonal, Hematology, MESH: Pil, Middle Aged, Nitrogen mustard, 3. Good health, multiple myeloma, C-Reactive Protein, 030220 oncology & carcinogenesis, MESH: Dexamethasone, Female, medicine.drug, Adult, Mucositis, medicine.medical_specialty, MESH: Myeloablative Agonists, Transplantation, Autologous, Article, Disease-Free Survival, 03 medical and health sciences, MESH: Melphalan, Internal medicine, MESH: C-Reactive Protein, medicine, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, Autologous transplantation, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, anti-interleukin-6, 030304 developmental biology, Aged, MESH: Drug Evaluation, Transplantation, Chemotherapy, MESH: Humans, business.industry, Interleukin-6, MESH: Adult, Myeloablative Agonists, medicine.disease, MESH: Interleukin-6, MESH: Male, Endocrinology, chemistry, MESH: Anti-Inflammatory Agents, MESH: Disease-Free Survival, Drug Evaluation, business, MESH: Female, Stem Cell Transplantation
Abstract

International audience; Interleukin-6 (IL-6) is a major survival factor for multiple myeloma (MM) cells preventing apoptosis induced by dexamethasone (DEX) or chemotherapy. In all, 24 consecutive patients with MM in first-line therapy received DEX for 4 days, followed by melphalan (HDM: 140 mg/m2) and autologous stem cell transplantation (ASCT). The anti-IL-6 monoclonal antibody (mAb) (B-E8) was given till haematological recovery, starting 1 day before DEX. Results were historically compared to MM patients treated with HDM 140 and 200 mg/m2. Our results show (1) that B-E8 was able to fully neutralize IL-6 activity in vivo before and after HDM as shown by inhibition of C reactive protein (CRP) production; (2) no haematological toxicity; (3) a significant reduction of mucositis and fever; (4) a median event-free survival of 35 months and an overall survival of 68.2% at 5 years with a median follow-up of 72 months; and (5) the overall daily IL-6 production progressively increased on and after 7 days post-HDM, with the increased serum CRP levels. In the 5/24 patients with uncontrolled CRP production, a large IL-6 production was detected (320 microg/day) that could not possibly be neutralized by B-E8. These data show the feasibility to neutralize IL-6 in vivo with anti-IL-6 mAb in the context of HDM.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results